Makaluvamine P | 377085-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Makaluvamine P
• 英文别名: 10-[2-(4-hydroxyphenyl)ethylamino]-2,7-dimethyl-2-aza-7-azoniatricyclo[6.3.1.04,12]dodeca-1(12),3,7,9-tetraen-11-one
• CAS: 377085-54-6
• 化学式: C20H22N3O2+
• 分子量: 336.4
• InChiKey: OLEMIURMTKKFSE-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  57.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Aaptamine and isoaaptamine and structural modifications thereof
  申请人：Pettit R. George

  公开号：US20050187240A1

  公开（公告）日：2005-08-25

  Disclosed herein is the isolation and elucidation of the structure of isoaptamine (2), and its conversion to numerous novel related compounds, which appear to have antimicrobial and/or cancer fighting properties. Also disclosed is the conversion of isoaaptamine (2) to the phosphate prodrug hystatin 1 (11), as well as the conversion of aaptamine to numerous compounds, including but not limited to: 9-demethyloxyaaptamine (3); 4-methylaaptamine (4); 1,4-dimethylaaptamine iodide (5); 4-N-methyl-8,9-dihydroxy-4H benzo[de][1,6]naphthyridine (7); 4-N-methyl-8 methoxy-9 hydroxy-4H benzo[de][1,6]naphthyridine (8); 1-H-Benzo[de][1-6]naphthyridinium salts (9a-c); hystatin 2 (10a); and others.

  本文披露了isoaptamine（2）结构的分离和阐明，以及其转化为许多具有抗微生物和/或抗癌特性的新相关化合物。还披露了isoaaptamine（2）转化为磷酸盐前药hystatin 1（11），以及aaptamine转化为许多化合物，包括但不限于：9-去甲氧基aaptamine（3）；4-甲基aaptamine（4）；1,4-二甲基aaptamine碘化物（5）；4-N-甲基-8,9-二羟基-4H苯并[de][1,6]萘啉（7）；4-N-甲基-8-甲氧基-9-羟基-4H苯并[de][1,6]萘啉（8）；1-H-苯并[de][1-6]萘啉盐（9a-c）；hystatin 2（10a）；等其他化合物。
• [EN] PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE PYRROLOQUINOLÉINE ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2018170019A1

  公开（公告）日：2018-09-20

  Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided. Formula (I), (II).

  提供了式（I）或（II）的吡咯喹啉化合物。在某些方面，这些吡咯喹啉化合物具有治疗作用，例如用于治疗细胞增殖性疾病。还提供了包括本公开的吡咯喹啉化合物的结合物。还提供了包括本公开的吡咯喹啉化合物和结合物的组成物，例如制药组成物。还提供了涉及给予本公开的吡咯喹啉化合物、结合物或组成物的治疗方法。还提供了包括吡咯喹啉化合物、结合物或组成物的试剂盒。式（I），（II）。
• Pyrroloquinolin compounds and methods of using same
  申请人：The Regents of the University of California

  公开号：US11020488B2

  公开（公告）日：2021-06-01

  Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.

  所提供的是式(1)或(II)的吡咯喹啉化合物。在某些方面，这些吡咯喹啉化合物具有治疗作用，例如用于治疗细胞增殖性疾病。还提供了包括本公开的吡咯喹啉化合物的共轭物。还提供了包括本公开的吡咯喹啉化合物和共轭物的组合物，例如药物组合物。此外，还提供了涉及施用本公开的吡咯喹啉化合物、共轭物或组合物的治疗方法。还提供了包括吡咯喹啉化合物、共轭物或组合物的试剂盒。
• PYRROLOQUINOLIN COMPOUNDS AND METHODS OF USING SAME
  申请人：The Regents of the University of California

  公开号：US20200129631A1

  公开（公告）日：2020-04-30

  Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.